71 completed, 9 terminated, 3 unknown, 2 active not recruiting. 61 Phase 2, 36 Phase 1, 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 61 | Completed 48, Terminated 7, Active not recruiting 2, Unknown 2, Recruiting 1, Withdrawn 1 |
| Phase 1 | 36 | Completed 30, Terminated 4, Unknown 1, Withdrawn 1 |
| Phase 3 | 4 | Completed 4 |
Follow tipifarnib: new trials by email Literature Review of tipifarnib trials Research Report on tipifarnib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma Tipifarnib, Naxitamab - Neuroblastoma | Phase 2 | Recruiting | Giselle Sholler | 98 | 2024-12-06 | 2026-09-03 |
| Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung Cancer Tipifarnib, Osimertinib - NSCLC | Phase 1 | Withdrawn | Kura Oncology, Inc. | 2023-02-01 | 2023-03-06 | |
| Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) Tipifarnib, Alpelisib - HNSCC | Phase 1 / Phase 2 | Completed | Kura Oncology, Inc. | 45 | 2021-12-07 | 2026-09-08 |
| Cardiovascular Safety Study of Tipifarnib in Patients With Advanced Solid Malignancies Tipifarnib - Advanced Solid Tumor | Phase 1 | Terminated | Kura Oncology, Inc. | 6 | 2021-05-06 | 2023-09-21 |
| Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial Tipifarnib - Malignant Solid Neoplasm, Recurrent Adrenal Gland Pheochromocytoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 5 | 2020-10-13 | 2026-11-13 |
| Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy Tipifarnib, HRAS Detection Assay - HRAS Gene Mutation, HNSCC | Phase 2 | Completed | Kura Oncology, Inc. | 296 | 2019-03-15 | 2024-06-21 |
| Tipifarnib in Advanced Squamous NSCLC With Oncogen HRAS MutAtionS Tipifarnib - Non Small Cell Lung Cancer | Phase 2 | Terminated | Spanish Lung Cancer Group | 9 | 2018-05-07 | 2025-03-05 |
| Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration and Biopsy - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 1377 | 2017-07-31 | 2026-11-13 |
| Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia, Other MDS/MPN, and Acute Myeloid Leukemia Tipifarnib - Leukemia, Myelomonocytic, Chronic | Phase 2 | Completed | Kura Oncology, Inc. | 44 | 2017-01-10 | 2024-07-17 |
| Tipifarnib in Subjects With Myelodysplastic Syndromes Tipifarnib - Myelodysplastic Syndromes | Phase 2 | Terminated | Kura Oncology, Inc. | 16 | 2016-06-01 | 2024-07-31 |
| Investigation of Tipifarnib in Treatment of Subjects With Peripheral T-Cell Lymphoma (PTCL) That Have Not Responded to Standard Therapy Tipifarnib - Relapsed or Refractory Peripheral T-Cell Lymphoma | Phase 2 | Completed | Kura Oncology, Inc. | 65 | 2016-02-25 | 2024-06-26 |
| Study of Tipifarnib in Patients With Previously-Treated, Advanced, HRAS Mutant Urothelial Carcinoma tipifarnib - Urothelial Carcinoma | Phase 2 | Unknown | Samsung Medical Center | 19 | 2015-11-12 | 2022-03-08 |
| Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations Tipifarnib - Thyroid Cancer, Squamous Cell Carcinoma Head and Neck Cancer (HNSCC) | Phase 2 | Completed | Kura Oncology, Inc. | 63 | 2015-05-13 | 2024-07-11 |
| Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia Tipifarnib, Laboratory Biomarker Analysis - Adult Acute Megakaryoblastic Leukemia, Adult Acute Monoblastic Leukemia | Phase 2 | Completed | National Cancer Institute (NCI) | 21 | 2011-05-01 | 2015-04-08 |
| Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed, Previously Untreated Acute Myeloid Leukemia tipifarnib, etoposide - Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Megakaryoblastic Leukemia (M7) | Phase 2 | Completed | National Cancer Institute (NCI) | 84 | 2008-01-01 | 2014-10-09 |
| Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery sorafenib tosylate, tipifarnib, temsirolimus - Recurrent Melanoma, Stage IV Melanoma | Phase 2 | Completed | National Cancer Institute (NCI) | 109 | 2007-08-01 | 2014-05-20 |
| Efficacy and Safety of the Farnesyl-transferase Inhibitor (Tipifarnib) in Mantle Cell Lymphoma ZARNESTRA (Tipifarnib) - Mantle Cell Lymphoma | Phase 2 | Terminated | Lymphoma Study Association | 11 | 2007-06-01 | 2018-08-23 |
| Tipifarnib and Combination Chemotherapy in Treating Patients With Stage II or Stage III Breast Cancer tipifarnib, paclitaxel, doxorubicin - Breast Cancer, Male Breast Cancer | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 60 | 2007-04-01 | 2021-02-16 |
| Tipifarnib, Cytarabine, and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia cytarabine, daunorubicin hydrochloride, tipifarnib - Leukemia | Phase 1 | Completed | University Health Network, Toronto | 24 | 2007-04-01 | 2015-07-23 |
| Study to Assess the Safety, Tolerability, and Efficacy of Tipifarnib Plus Bortezomib in the Treatment of Acute Myeloid Leukemia Tipifarnib plus Bortezomib - Acute Myeloid Leukemia | Phase 2 | Unknown | University of Bologna | 72 | 2007-03-01 | 2009-08-14 |
Showing 20 of 89. Sign in to see all of them.
Leukemia, Myeloid, Acute (17) · Breast Neoplasms (11) · Leukemia, Erythroblastic, Acute (11) · Leukemia, Megakaryoblastic, Acute (11) · Leukemia, Monocytic, Acute (11) · Leukemia, Myelomonocytic, Acute (11) · Congenital Abnormalities (10) · Glioblastoma (7) · Leukemia (7) · Pancreatic Neoplasms (6) · Recurrence (6) · Anemia, Refractory, with Excess of Blasts (5) · Carcinoma, Non-Small-Cell Lung (5) · Gliosarcoma (5) · Leukemia, Basophilic, Acute (5)
National Cancer Institute (NCI) (42) · Kura Oncology, Inc. (9) · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (6) · H. Lee Moffitt Cancer Center and Research Institute (3) · Abramson Cancer Center at Penn Medicine (2) · Institut Claudius Regaud (2) · M.D. Anderson Cancer Center (2) · NYU Langone Health (2) · SWOG Cancer Research Network (2) · The University of Texas Health Science Center at San Antonio (2) · University Health Network, Toronto (2) · City of Hope Medical Center (1) · Emory University (1) · Fox Chase Cancer Center (1) · Giselle Sholler (1)
United States (74) · Canada (5) · France (4) · South Korea (4) · Spain (4) · United Kingdom (4) · Australia (3) · Belgium (3) · Germany (3) · Italy (3) · Netherlands (3) · Greece (2) · Puerto Rico (2) · Austria (1) · Denmark (1)
Judith Karp (4) · Jeffrey Lancet (2) · Melissa Alsina, M.D. (2) · Stephen Michael Hahn, MD (2) · Timothy Cloughesy (2) · Abraham Chachoua, MD (1) · Alan K. Burnett, MD, FRCP (1) · Alex Adjei (1) · Anthony W. Tolcher, MD (1) · Banu Arun (1) · Brigitte C. Widemann, MD (1) · Brigitte Widemann, M.D. (1)
PMID 12663718, PMID 15570084, PMID 15709195, PMID 15711184, PMID 15812833, PMID 16133800, PMID 16170172, PMID 16683076, PMID 16877733, PMID 17851757, PMID 19092853, PMID 19109557, PMID 19153124, PMID 19470696, PMID 20860038, PMID 21725056, PMID 22001391, PMID 23228035, PMID 23566417, PMID 23676418, PMID 23996484, PMID 24068539, PMID 24500418, PMID 33591402, PMID 33750196, PMID 35353553, PMID 37944074, PMID 38991123, PMID 41166674, PMID 42686334, PMID 42853672
N01CM62204 (5), U01CA070095 (5), P30CA015083 (4), U10CA032102 (4), N01CM62202 (3), N01CM17104 (2), P30CA016672 (2), P30CA054174 (2), P30CA076292 (2), U01CA062399 (2), U01CA062461 (2), U01CA062505 (2), U01CA069854 (2), U01CA069912 (2), U10CA021115 (2)